ClinicalTrials.gg
RecruitingNCT07715175D2570-107Updated Oct 13, 2026

The Study is to Investigate D-2570 in Participants With Different Levels of Kidney Function.

A Phase 1 interventional study of D-2570 in Renal Impairment, sponsored by InventisBio Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by InventisBio Co., Ltd · Phase 1, Interventional, and Other

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 13, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies in Renal Insufficiency with a site in China — 16 open to participants now, 16 under way, none of them phase 3. Renal Insufficiency · China.

Planned enrollment
25th of 48
40 · median 41
Started
2026
with 8 others
Phase 1
22 of 61
4 open now
Primary completion
2026-11
later than 5 of 15 live
Registered
59th of 61
by date

Among the 61 studies in Renal Insufficiency with a site in China, this one is the 25th largest by planned enrollment of the 48 interventional ones that give a count, is one of 9 that started in 2026, is one of 22 in phase 1, reaches primary completion later than 5 of the 15 other live ones, and was the 59th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

16 of the 61 studies in Renal Insufficiency with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Renal Insufficiency with a site in China, or all of them as a file.
02

Study summary

This study is divided two parts into: Part A and Part B. Part A will recruit 24 research participants, and Part B will recruit 16 research participants.

Read the detailed description

Subjects of this study will be admitted to the Phase I ward of the research center one day before drug administration . On the first day, subjects will orally take a single dose of D-2570. The researchers will collect a series of blood and urine samples before and after drug D - 2570 administration to determine the drug concentration and evaluate the pharmacokinetic characteristics. The subjects can leave site after completing the safety evaluation.

03

Conditions studied

  • Renal Impairment

Browse trials for

Keywords

  • Renal Impairment
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily participate in this study after adequate , sign the written informed consent form, and agree to comply with all procedures specified in the study protocol;
  • Aged 18 to 70 years (inclusive). Age matching will be conducted between the normal renal function group and the matched renal impairment group with a mean difference within ±10 years;
  • Male and female participants are eligible. Gender matching will be performed between the normal renal function group and the matched renal impairment group with a difference of no more than 1 subject;
  • Male participants weigh no less than 50 kg, and female participants weigh no less than 45 kg. (BMI) = weight (kg) / height squared (m²), ranging from 19 to 30 kg/m² (inclusive). Weight matching will be conducted between the normal renal function group and the matched renal impairment group with a mean difference within ±10 kg;

Exclusion criteria

Exclusion Criteria:

  • Allergic constitution (e.g., allergy to pollen, two or more types of drugs/foods), or history of atopic diseases such as asthma and urticaria, or known to the study drug or its ;
  • Positive T-SPOT result at screening. Combined with clinical signs and chest posteroanterior X-ray findings, the participant is judged by the investigator to have active pulmonary tuberculosis;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    participants with normal renal function

    Subjects will receive a single dose of D-2570

    Drug: D-2570

  • Experimental
    participants with Mild Renal Impairment

    Subjects will receive a single dose of D-2570 (Part B)

    Drug: D-2570

  • Experimental
    participants with Moderate Renal Impairment

    Subjects will receive a single dose of D-2570 (Part A)

    Drug: D-2570

  • Experimental
    participants with Severe Renal Impairment

    Subjects will receive a single dose of D-2570 (Part A)

    Drug: D-2570

Interventions

  • DrugD-2570

    receive a single dose of D-2570

06

What researchers measure

Primary outcomes

  1. The main PK parameters -Time to maximum measured plasma concentration -Tmax

    The main PK parameters -Time to maximum measured plasma concentration -Tmax

    Time frame: Through study completion (approximately Day9)

  2. Maximum observed plasma concentration-Cmax

    Maximum observed plasma concentration-Cmax

    Time frame: Through study completion (approximately Day9)

  3. The main PK parameters Half-life -t1/2

    The main PK parameters Half-life -t1/2

    Time frame: Through study completion (approximately Day9)

  4. The main PK parameters#Area under the plasma concentration versus time curve-AUC

    The main PK parameters#Area under the plasma concentration versus time curve-AUC

    Time frame: Through study completion (approximately Day9)

  5. The main PK parameters-CL/F (apparent clearance)

    The main PK parameters-CL/F (apparent clearance)

    Time frame: Through study completion (approximately Day9)

  6. The main PK parameters-Vz/F (apparent volume of distribution)

    The main PK parameters-Vz/F (apparent volume of distribution)

    Time frame: Through study completion (approximately Day9)

  7. The cumulative excretion amount (Aeu)

    The cumulative excretion (Aeu) of D - 2570 and its metabolites in urine

    Time frame: Through study completion (approximately Day9)

  8. The fraction of drug excreted in urine (Feu)

    The fraction of drug excreted in urine (Feu) of D - 2570 and its metabolites in urine

    Time frame: Through study completion (approximately Day9)

  9. The renal clearance rate (CLR)

    The renal clearance rate (CLR)of D - 2570 and its metabolites in urine

    Time frame: Through study completion (approximately Day9)

Secondary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v6.0

    Incidence of adverse events

    Time frame: Through study completion (approximately Day9)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Nov 2026, 3 months after the start.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 3 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 20, 2026
StartActual
Aug 8, 2026
Primary completionEst.
Nov 21, 2026
CompletionEst.
Nov 21, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
The First Affiliated Hospital of Anhui Medical University is now Recruiting
Oct 13, 2026
Start date
Aug 9, 2026→Aug 8, 2026 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    The First Affiliated Hospital of Anhui Medical University is now Recruiting
    Start date Aug 9, 2026→Aug 8, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07715175
Responsible party
Sponsor
First posted
Jul 20, 2026
Start date
Aug 8, 2026
Primary completion
Nov 21, 2026 (estimated)
Completion
Nov 21, 2026 (estimated)
Last update
Oct 13, 2026

Study contacts

Huan Zhou, Doctor
Contact
zhouhuanbest@vip.163.com
13665527160
Dingli Yao, Bachelor's
Contact
dingli.yao@inventisbio.com
15538261075
Huan Zhou, Doctor
principal investigator · The First Affiliated Hospital of Anhui Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: D-2570

Start the discussion